Home › Funds › EVENTIDE ASSET MANAGEMENT, LLC › CLDX

EVENTIDE ASSET MANAGEMENT, LLC position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

EVENTIDE ASSET MANAGEMENT, LLC reported holding 1,896,637 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$61.5M, representing 0.86% of its reported portfolio and ranking #33 among its reported holdings. EVENTIDE ASSET MANAGEMENT, LLC has disclosed CLDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.90M sh
Reported value held$61.46M
Portfolio Weight0.86%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How EVENTIDE ASSET MANAGEMENT, LLC's CLDX position evolved

EVENTIDE ASSET MANAGEMENT, LLC first disclosed a stake in CLDX in Q3 2023 at 1,600,000 shares (US$44.0M). The position peaked in Q4 2023 at 3,630,013 shares, worth US$144.0M. Across 13 filings, EVENTIDE ASSET MANAGEMENT, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,896,637 shares valued at US$61.5M — an increase of 859,637 shares quarter over quarter.. Notable position changes include a 127% increase in Q4 2023 (shares rose 6% over the following quarter), a 64% trim in Q2 2025 (shares rose 27% over the following quarter), a 83% increase in Q3 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.60M $44.03M New
Q4 2023 3.63M $143.97M Add
Q1 2024 3.12M $130.91M Reduce
Q2 2024 3.33M $123.14M Add
Q3 2024 3.33M $113.25M Hold
Q4 2024 3.75M $94.84M Add
Q1 2025 3.75M $68.18M Hold
Q2 2025 1.36M $27.60M Reduce
Q3 2025 1.86M $48.10M Add
Q4 2025 1.64M $44.61M Reduce
Q1 2026 1.04M $32.89M Reduce
Q2 2026 1.04M $38.59M Hold
Q3 2026 1.90M $61.46M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 40 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has EVENTIDE ASSET MANAGEMENT, LLC held CLDX?

EVENTIDE ASSET MANAGEMENT, LLC has disclosed CLDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is EVENTIDE ASSET MANAGEMENT, LLC's current position in CLDX?

As of Q3 2026, EVENTIDE ASSET MANAGEMENT, LLC holds 1.90M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $61.46M, representing 0.86% of its reported portfolio and ranking #33.

Has EVENTIDE ASSET MANAGEMENT, LLC been buying or selling CLDX?

In the latest 13F filing (Q3 2026), EVENTIDE ASSET MANAGEMENT, LLC increased its position in CLDX. The position peaked in Q4 2023 at 3.63M shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.